Morphosys: Das sind die Ziele von CEO Kress & Co - DER AKTIONÄR
Two by 2025: MorphoSys Consolidates Research, Retains Commercialization Goal
Jean-Paul Kress | Les Amateurs Virtuoses
Morphosys: Missmanagement bei Deutschlands einstigem Biotechstar - manager magazin
Jean-Paul Kress - Biografie
Chutes & Ladders—Biogen executive Kress takes over the reins of Syntimmune | Fierce Biotech
Jean-Paul Kress Appointed EVP and President, International and Head of Global Therapeutic Operations | Business Wire
MS Therapies are Focus of Abarca-Biogen Value-based Reimbursement Contract
Biogen on Twitter: "Jean-Paul Kress, MD, joins Biogen today as EVP & President, International & Head, Global Therapeutic Operations https://t.co/bJaIERREZ3 https://t.co/BMu0PTC99l" / Twitter
Kress becomes new CEO of MorphoSys - BioM
Exhibit 99.1
Chutes & Ladders—Biogen executive Kress takes over the reins of Syntimmune | Fierce Biotech
Abarca Health, Biogen ally on multiple sclerosis coverage – News is My Business
New CEO at Morphosys - European Biotechnology
Imraldi, Biogen's Humira Biosimilar, Gains EC Approval - Drug Discovery and Development
Abarca Announces Innovative Value-Based Contract with Biogen
Jean-Paul Kress, Morphosys AG: Profile and Biography - Bloomberg Markets
Chutes & Ladders—Biogen executive Kress takes over the reins of Syntimmune | Fierce Biotech
The Top 25 Healthcare Technology Leaders of Massachusetts for 2023 | The Healthcare Technology Report.
Jean-Paul Kress Net Worth (2023) | wallmine
David Khougazian appointed president of Sanofi Pasteur MSD - PMLiVE
Jean-Paul Kress M.D. — Executive VP, President of International, Head of Global Therapeutic Operations at Biogen | Comparably
